Autoimmune encephalitis is a condition in which the body’s immune system mistakenly attacks healthy brain cells, causing inflammation that can rapidly alter a person’s behavior, thinking, and consciousness. It progresses over days to weeks, not months or years, and is often treatable if caught early. Left untreated, it can lead to seizures, coma, and lasting cognitive damage.
How the Immune System Turns on the Brain
In a healthy immune response, antibodies target invaders like bacteria or viruses. In autoimmune encephalitis, the immune system produces antibodies that instead latch onto proteins on the surface of brain cells. These proteins normally help brain cells communicate with each other. When antibodies bind to them, they pull the proteins off the cell surface or block their function, disrupting the signaling networks that underpin memory, movement, speech, and awareness.
The most common form targets a receptor involved in learning and memory (the NMDA receptor). Antibodies cross-link these receptors and drag them inside the cell, effectively silencing a key communication channel. Other forms target different surface proteins. Some antibodies block cell-to-cell adhesion molecules, while others reduce the number of receptors that excite brain cells into action. Each antibody type produces a somewhat different pattern of symptoms, but the underlying problem is the same: the immune system interfering with normal brain signaling.
A separate category involves antibodies directed at proteins inside brain cells rather than on their surface. These antibodies don’t directly damage neurons. Instead, they act as markers of a deeper immune attack driven by certain white blood cells that infiltrate brain tissue and destroy neurons directly. This type is more often linked to an underlying cancer and tends to be harder to reverse.
What It Feels Like: Symptoms and Progression
Autoimmune encephalitis typically develops over days to a few weeks. Early symptoms often look psychiatric: sudden personality changes, paranoia, hallucinations, agitation, or severe anxiety in someone with no prior psychiatric history. This is one reason the condition is frequently misdiagnosed as a psychiatric disorder at first.
As the disease progresses, neurological symptoms emerge. These can include memory problems (especially difficulty forming new memories), confusion, seizures, involuntary movements or facial twitching, difficulty speaking or sudden loss of speech, and episodes of unresponsiveness. In severe cases, the body’s automatic functions start to fail, causing dangerous fluctuations in heart rate, blood pressure, and breathing. Some patients become comatose.
The specific combination of symptoms depends on which antibody is involved. In NMDA receptor encephalitis, the most common subtype, a characteristic pattern unfolds: behavioral changes and psychosis appear first, followed by seizures, involuntary movements, declining consciousness, and breathing instability. Doctors look for at least four of six major symptom groups (behavioral or cognitive changes, speech problems, seizures, movement abnormalities, reduced consciousness, and autonomic instability) to suspect this form. In limbic encephalitis, another common subtype, memory loss and seizures centered in the brain’s temporal lobes tend to dominate, and persistent amnesia can develop if treatment is delayed.
How It Differs in Children
Children with autoimmune encephalitis often present differently than adults. Rather than a single dominant symptom, they tend to show a mix of neuropsychiatric problems all at once: abnormal behavior (reported in about 84% of pediatric cases), psychiatric symptoms like hallucinations and delusions (67%), seizures (69%), speech regression (59%), and insomnia (55%). Involuntary facial movements and writhing limb motions are also common in younger patients.
The developing brain responds differently to immune attack. Children who present with severe encephalopathy, prolonged seizures, or coma at the outset generally face a longer, more complicated recovery. While many children recover significant neurological function, some are left with lasting difficulties in memory, attention, and executive function that can affect school performance for years. Autoimmune encephalitis in children is distinct from pediatric acute-onset neuropsychiatric syndrome (PANS), which tends to cycle between flare-ups and improvements rapidly, sometimes within hours, and typically does not impair core cognitive abilities the way encephalitis does.
Distinguishing It From Psychiatric Illness
Because early symptoms so closely mimic psychiatric conditions, some patients spend weeks or months in psychiatric care before anyone suspects an autoimmune cause. The key red flags that point toward encephalitis rather than a primary psychiatric disorder include a rapid onset (over days to weeks rather than a gradual slide), the appearance of neurological signs alongside psychiatric symptoms, and a combination of features that don’t fit neatly into any single psychiatric diagnosis.
Specific warning signs include new-onset seizures, involuntary movements, confusion or disorientation, memory gaps, altered consciousness, and catatonia appearing alongside psychotic or mood symptoms. When a young person with no psychiatric history suddenly develops severe psychosis along with any of these neurological features, autoimmune encephalitis should be on the list of possibilities. Antibodies associated with encephalitis have been detected in patients originally diagnosed with schizophrenia spectrum disorders, mood disorders, obsessive-compulsive disorder, and even some cases initially labeled as ADHD or autism spectrum disorders.
How It Is Diagnosed
Diagnosis follows a stepwise process. A case is considered “possible” autoimmune encephalitis when someone develops memory problems, altered mental status, or psychiatric symptoms over less than three months, along with at least one supporting finding: new neurological deficits, unexplained seizures, elevated white blood cells in spinal fluid, or MRI changes consistent with brain inflammation. Other causes, such as infections and metabolic problems, must be ruled out.
Brain MRI may show bright signals in the temporal lobes or cortical regions on certain imaging sequences, but MRI is entirely normal in many confirmed cases. This is an important point: a clean MRI does not rule out the condition. EEG (brainwave testing) can reveal seizure activity or, in NMDA receptor encephalitis specifically, a distinctive pattern called “extreme delta brush.” Spinal fluid analysis often shows mild inflammation, with elevated white blood cells or the presence of oligoclonal bands, though some patients have unremarkable spinal fluid early on.
The definitive diagnosis depends on identifying the specific antibody in blood or spinal fluid. Testing spinal fluid directly is more reliable than blood testing alone, because some antibodies are present at higher concentrations in the central nervous system. However, antibody results can take days to weeks to return, and doctors are encouraged to begin treatment before results arrive if clinical suspicion is strong enough.
Treatment: First and Second Lines
Autoimmune encephalitis is one of the more treatable causes of serious brain inflammation, but the window matters. Earlier treatment is associated with better outcomes.
First-line treatment typically involves high-dose corticosteroids given intravenously for three to seven days to suppress the immune response and reduce inflammation quickly. If steroids alone aren’t enough, or if the clinical picture suggests antibody-driven disease from the start, doctors add intravenous immunoglobulin (a concentrated dose of donated antibodies that helps regulate the immune system) or plasma exchange, a procedure that filters harmful antibodies out of the blood over five to ten sessions. In severe cases, such as patients in a coma or experiencing dangerous autonomic instability, these therapies may be combined from the beginning rather than tried one at a time.
If there’s no meaningful improvement after two to four weeks of first-line treatment, second-line therapy is introduced. About 80% of specialists reach for rituximab, a medication that depletes the specific white blood cells responsible for producing the offending antibodies. A smaller number use cyclophosphamide, a broader immune suppressant. In pediatric cases, roughly 55% of children receive a single second-line agent, and about 18% require a third line of treatment. Children who received combined immunotherapy showed the greatest reduction in disability scores over long-term follow-up.
If a tumor is found to be driving the immune response (ovarian teratomas are a well-known trigger in NMDA receptor encephalitis), removing it is a critical part of treatment. The immune attack often won’t fully resolve until the tumor is gone.
Recovery and the Risk of Relapse
Recovery from autoimmune encephalitis is real but slow. Most patients experience a gradually progressive improvement over one to two years. The trajectory is not linear; good days and setbacks are common, and cognitive recovery often lags behind the resolution of more dramatic symptoms like seizures or psychosis. Memory, attention, processing speed, and fatigue can remain issues well into recovery even when someone appears outwardly improved.
Relapse is a recognized risk. In a study of 507 patients with NMDA receptor encephalitis, 9% experienced at least one relapse. Among those who relapsed, 73% had a single recurrence, 18% had two, and 8% had three. Relapses are more common in patients who did not receive adequate immunotherapy during their initial episode or who had delayed treatment. Ongoing immune-suppressing medication after the acute phase is often used to reduce this risk, though the ideal duration of maintenance therapy is still a matter of clinical judgment tailored to each person’s antibody type and severity.
Why It Is Being Recognized More Often
Autoimmune encephalitis is not new, but awareness and diagnostic capability have expanded dramatically. Admissions identified as autoimmune encephalitis at one tertiary center rose from 3.8 per 100,000 yearly admissions in 2010 to 18.8 per 100,000 in 2020. Much of this increase reflects better antibody testing and growing recognition among neurologists and psychiatrists rather than a true surge in cases. The condition disproportionately affects women and younger adults, though it can occur at any age, including in young children and older adults. As testing becomes more routine in patients with unexplained neuropsychiatric decline, the number of identified cases will likely continue to rise.